These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 23998618)

  • 1. [Gene mutation and myelodysplastic syndromes with ring sideroblast excess].
    Meng FK; Huang LF; Zhou JF; Sun HY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Aug; 21(4):1088-90. PubMed ID: 23998618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SF3B1-mutated myelodysplastic syndrome with ring sideroblasts harbors more severe iron overload and corresponding over-erythropoiesis.
    Zhu Y; Li X; Chang C; Xu F; He Q; Guo J; Tao Y; Liu Y; Liu L; Shi W
    Leuk Res; 2016 May; 44():8-16. PubMed ID: 26970172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts.
    Malcovati L; Karimi M; Papaemmanuil E; Ambaglio I; Jädersten M; Jansson M; Elena C; Gallì A; Walldin G; Della Porta MG; Raaschou-Jensen K; Travaglino E; Kallenbach K; Pietra D; Ljungström V; Conte S; Boveri E; Invernizzi R; Rosenquist R; Campbell PJ; Cazzola M; Hellström Lindberg E
    Blood; 2015 Jul; 126(2):233-41. PubMed ID: 25957392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Splicing factor 3b subunit 1 (Sf3b1) haploinsufficient mice display features of low risk Myelodysplastic syndromes with ring sideroblasts.
    Visconte V; Tabarroki A; Zhang L; Parker Y; Hasrouni E; Mahfouz R; Isono K; Koseki H; Sekeres MA; Saunthararajah Y; Barnard J; Lindner D; Rogers HJ; Tiu RV
    J Hematol Oncol; 2014 Dec; 7():89. PubMed ID: 25481243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of SF3B1 mutations in Korean patients with myelodysplastic syndromes and myelodysplasia/myeloproliferative neoplasms with ring sideroblasts.
    Seo JY; Lee KO; Kim SH; Kim K; Jung CW; Jang JH; Kim HJ
    Ann Hematol; 2014 Apr; 93(4):603-8. PubMed ID: 24141330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value.
    Patnaik MM; Lasho TL; Hodnefield JM; Knudson RA; Ketterling RP; Garcia-Manero G; Steensma DP; Pardanani A; Hanson CA; Tefferi A
    Blood; 2012 Jan; 119(2):569-72. PubMed ID: 22096241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and genetic characteristics of congenital sideroblastic anemia: comparison with myelodysplastic syndrome with ring sideroblast (MDS-RS).
    Ohba R; Furuyama K; Yoshida K; Fujiwara T; Fukuhara N; Onishi Y; Manabe A; Ito E; Ozawa K; Kojima S; Ogawa S; Harigae H
    Ann Hematol; 2013 Jan; 92(1):1-9. PubMed ID: 22983749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SF3B1 mutations are infrequently found in non-myelodysplastic bone marrow failure syndromes and mast cell diseases but, if present, are associated with the ring sideroblast phenotype.
    Visconte V; Tabarroki A; Rogers HJ; Hasrouni E; Traina F; Makishima H; Hamilton BK; Liu Y; O'Keefe C; Lichtin A; Horwitz L; Sekeres MA; Hsieh FH; Tiu RV
    Haematologica; 2013 Sep; 98(9):e105-7. PubMed ID: 23831919
    [No Abstract]   [Full Text] [Related]  

  • 9. Prognostic impact of
    Farrukh F; Abdelmagid M; Mangaonkar A; Patnaik M; Al-Kali A; Elliott MA; Begna KH; Hook CC; Hogan WJ; Pardanani A; Litzow MR; Ketterling RP; Gangat N; Arber DA; Orazi A; He R; Reichard K; Tefferi A
    Haematologica; 2024 Aug; 109(8):2525-2532. PubMed ID: 38450522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes.
    Visconte V; Rogers HJ; Singh J; Barnard J; Bupathi M; Traina F; McMahon J; Makishima H; Szpurka H; Jankowska A; Jerez A; Sekeres MA; Saunthararajah Y; Advani AS; Copelan E; Koseki H; Isono K; Padgett RA; Osman S; Koide K; O'Keefe C; Maciejewski JP; Tiu RV
    Blood; 2012 Oct; 120(16):3173-86. PubMed ID: 22826563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Refractory anemia with ring sideroblasts.
    Malcovati L; Cazzola M
    Best Pract Res Clin Haematol; 2013 Dec; 26(4):377-85. PubMed ID: 24507814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells.
    Dolatshad H; Pellagatti A; Fernandez-Mercado M; Yip BH; Malcovati L; Attwood M; Przychodzen B; Sahgal N; Kanapin AA; Lockstone H; Scifo L; Vandenberghe P; Papaemmanuil E; Smith CW; Campbell PJ; Ogawa S; Maciejewski JP; Cazzola M; Savage KI; Boultwood J
    Leukemia; 2015 May; 29(5):1092-103. PubMed ID: 25428262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical importance of SF3B1 mutations in Chinese with myelodysplastic syndromes with ring sideroblasts.
    Cui R; Gale RP; Xu Z; Qin T; Fang L; Zhang H; Pan L; Zhang Y; Xiao Z
    Leuk Res; 2012 Nov; 36(11):1428-33. PubMed ID: 22921018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring the mechanistic link between SF3B1 mutation and ring sideroblast formation in myelodysplastic syndrome.
    Ochi T; Fujiwara T; Ono K; Suzuki C; Nikaido M; Inoue D; Kato H; Onodera K; Ichikawa S; Fukuhara N; Onishi Y; Yokoyama H; Nakamura Y; Harigae H
    Sci Rep; 2022 Aug; 12(1):14562. PubMed ID: 36028755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts.
    Visconte V; Makishima H; Jankowska A; Szpurka H; Traina F; Jerez A; O'Keefe C; Rogers HJ; Sekeres MA; Maciejewski JP; Tiu RV
    Leukemia; 2012 Mar; 26(3):542-5. PubMed ID: 21886174
    [No Abstract]   [Full Text] [Related]  

  • 16. Hemopoietic-specific Sf3b1-K700E knock-in mice display the splicing defect seen in human MDS but develop anemia without ring sideroblasts.
    Mupo A; Seiler M; Sathiaseelan V; Pance A; Yang Y; Agrawal AA; Iorio F; Bautista R; Pacharne S; Tzelepis K; Manes N; Wright P; Papaemmanuil E; Kent DG; Campbell PC; Buonamici S; Bolli N; Vassiliou GS
    Leukemia; 2017 Mar; 31(3):720-727. PubMed ID: 27604819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SF3B1 mutations in patients with myelodysplastic syndromes: the mutation is stable during disease evolution.
    Lin CC; Hou HA; Chou WC; Kuo YY; Wu SJ; Liu CY; Chen CY; Tseng MH; Huang CF; Lee FY; Liu MC; Liu CW; Tang JL; Yao M; Huang SY; Hsu SC; Ko BS; Tsay W; Chen YC; Tien HF
    Am J Hematol; 2014 Aug; 89(8):E109-15. PubMed ID: 24723457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Refractory anemia with ring sideroblasts and RARS with thrombocytosis.
    Patnaik MM; Tefferi A
    Am J Hematol; 2015 Jun; 90(6):549-59. PubMed ID: 25899435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic impact of mutations in spliceosomal genes for myelodysplastic syndrome patients without ring sideroblasts.
    Kang MG; Kim HR; Seo BY; Lee JH; Choi SY; Kim SH; Shin JH; Suh SP; Ahn JS; Shin MG
    BMC Cancer; 2015 Jun; 15():484. PubMed ID: 26115659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
    Malcovati L; Papaemmanuil E; Bowen DT; Boultwood J; Della Porta MG; Pascutto C; Travaglino E; Groves MJ; Godfrey AL; Ambaglio I; Gallì A; Da Vià MC; Conte S; Tauro S; Keenan N; Hyslop A; Hinton J; Mudie LJ; Wainscoat JS; Futreal PA; Stratton MR; Campbell PJ; Hellström-Lindberg E; Cazzola M;
    Blood; 2011 Dec; 118(24):6239-46. PubMed ID: 21998214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.